Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VIPR2 | P41587 | 19/20 | 0.60 |
| ▸ | MMP2 | P08253 | 1/20 | 0.52 |
| ▸ | MMP9 | P14780 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6465753 | 0.91 | VIPR2 (0.58) | VIPR2MMP2MMP9 | |
| SCHEMBL6464128 | 0.91 | VIPR2 (0.59) | VIPR2MMP2MMP9 | |
| SCHEMBL6464832 | 0.91 | VIPR2 (0.65) | VIPR2MMP2MMP9 | |
| SCHEMBL6466122 | 0.86 | VIPR2 (0.69) | VIPR2MMP2MMP9 | |
| SCHEMBL6468083 | 0.85 | VIPR2 (0.62) | VIPR2MMP2MMP9 | |
| SCHEMBL6469322 | 0.85 | VIPR2 (0.64) | VIPR2MMP2MMP9 | |
| SCHEMBL7300250 | 0.85 | VIPR2 (0.70) | VIPR2MMP2MMP9 | |
| SCHEMBL7300253 | 0.85 | VIPR2 (0.70) | VIPR2MMP2MMP9 | |
| SCHEMBL6465865 | 0.84 | VIPR2 (0.61) | VIPR2MMP9 | |
| SCHEMBL6463819 | 0.84 | VIPR2 (0.67) | VIPR2MMP2MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050038019-A1 | Hydroxy substituted amides for the treatment of alzheimer's disease | PHARMACIA & UPJOHN | 2005-02-17 | — | — | US | claimed |
| US-20050038019-A1 | Hydroxy substituted amides for the treatment of alzheimer's disease | PHARMACIA & UPJOHN | 2005-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038019-A1 | Hydroxy substituted amides for the treatment of alzheimer's disease | BACE1, APP, BACE2 | VIPR2 2131/4885MMP2 357/4885MMP9 526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.